Market Overview

Seattle Genetics Presents Encouraging ADCETRIS Data in CD30-Positive Non-Hodgkin Lymphomas and Other Malignancies

Seattle Genetics (NASDAQ: SGEN) today summarized ADCETRIS
(brentuximab vedotin) and CD30 expression data in non-Hodgkin lymphomas
and other malignancies from multiple presentations at the 54th
American Society of Hematology (ASH) Annual Meeting and Exposition being
held December 8-11, 2012 in Atlanta, GA. Highlights include encouraging
interim data from a phase II clinical trial of ADCETRIS in non-Hodgkin
lymphoma and long-term follow up from a pivotal clinical trial of
ADCETRIS in relapsed or refractory systemic anaplastic large cell
lymphoma (sALCL). In addition, investigators presented data describing
the expression of CD30 in DLBCL and case studies on ADCETRIS in patients
with systemic mastocytosis. ADCETRIS is an antibody-drug conjugate (ADC)
directed to CD30.

See full press release

Posted-In: News Guidance Management

 

Related Articles (SGEN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters